Nivolumab plus ipilimumab immunotherapy-related irAEs

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2024年 / 2035卷 / 1期
关键词：
D O I：
10.1007/s40278-024-70759-z
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：9 / 9
相关论文
共 50 条
  • [31] Characterization of an immunotherapy-related hepatitis cohort
    Tjandra, D.
    Salehi, O.
    Trinh, A.
    Perera, P.
    Haridy, J.
    Majeed, A.
    Boussioutas, A.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 101 - 102
  • [32] Nivolumab and Ipilimumab Immunotherapy-Induced Colitis and Hepatitis
    Ballecer, Eric
    Sy, Alexander
    Miller, Jennifer
    Mago, Sheena
    Sofer, Tova
    Malet, Peter
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2018, 113 : S1277 - S1277
  • [33] What Will Be the Next Partner for Combination Immunotherapy With Nivolumab and Ipilimumab?
    Luke, Jason J.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (10) : 483 - 485
  • [34] Multiple Immunotherapy-Related Cardiovascular Sequelae
    Menachery, Sherin M.
    Chuquin, David
    Sindel, Ariel
    Poklepovic, Andrew
    Abbate, Antonio
    Bottinor, Wendy
    CJC OPEN, 2023, 5 (02) : 170 - 172
  • [35] Treatment-related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumab
    Satzger, Imke
    Ivanyi, Philipp
    Laenger, Florian
    Kreipe, Hans-Heinrich
    Schaper-Gerhardt, Katrin
    Beutel, Gernot
    Cornberg, Markus
    Gutzmer, Ralf
    EUROPEAN JOURNAL OF CANCER, 2018, 93 : 150 - 153
  • [36] Long-term Perspective with Nivolumab plus Ipilimumab
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (09)
  • [37] Induction Exposure Dose of Ipilimumab and Failure of Adjuvant Nivolumab Plus Ipilimumab in Melanoma
    Augustin, Ryan C.
    Luke, Jason J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (03) : 443 - +
  • [38] Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma
    Wolchok, Jedd D.
    Chiarion-Sileni, Vanna
    Gonzalez, Rene
    Grob, Jean-Jacques
    Rutkowski, Piotr
    Lao, Christopher D.
    Cowey, C. Lance
    Schadendorf, Dirk
    Wagstaff, John
    Dummer, Reinhard
    Ferrucci, Pier Francesco
    Smylie, Michael
    Butler, Marcus O.
    Hill, Andrew
    Marquez-Rodas, Ivan
    Haanen, John B. A. G.
    Guidoboni, Massimo
    Maio, Michele
    Schoffski, Patrick
    Carlino, Matteo S.
    Lebbe, Celeste
    McArthur, Grant
    Ascierto, Paolo A.
    Daniels, Gregory A.
    Long, Georgina, V
    Bas, Tuba
    Ritchings, Corey
    Larkin, James
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (02) : 127 - +
  • [39] Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
    Zhou, Shi
    Khanal, Samrat
    Zhang, Haijun
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2019, 15 : 211 - 221
  • [40] NIVOLUMAB PLUS IPILIMUMAB IS WELL TOLERATED AND ACTIVE IN NSCLC
    不详
    CANCER DISCOVERY, 2017, 7 (02) : 124 - 124
12345